ADC Therapeutics SA

Stock Chart, Company Information, and Scan Results

$4.10(as of Mar 6, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

ADC Therapeutics SA Company Information, Fundamentals, and Technical Indicators

Stock Price$4.10
Ticker SymbolADCT
ExchangeNyse
SectorHealthcare
IndustryBiotechnology
Employees263
CountyUSA
Market Cap$525.2M
EBIDTA-121.5M
10-Day Moving Average4.21
P/E Ratio-3.42
20-Day Moving Average4.12
Forward P/E Ratio0.00
50-Day Moving Average3.83
Earnings per Share-1.41
200-Day Moving Average3.57
Profit Margin-249.38%
RSI54.85
Shares Outstanding123.9M
ATR0.25
52-Week High4.80
Volume1,516,775
52-Week Low1.05
Most Recent Support Level3.94
Book Value-238.2M
Most Recent Resistance Level4.41
P/B Ratio-2.40
Upper Keltner4.69
P/S Ratio7.60
Lower Keltner3.55
Debt-to-Equity Ratio4.69
Next Earnings Date03/12/2026
Cash Surplus172.7M
Next Ex-Dividend DateUnknown

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADC Therapeutics SA In Our Stock Scanner

As of Mar 06, 2026
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Hammer CandleScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.